Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Plus Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05559879Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2023
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, dostarlimab in Gynecologic carcinosarcoma (GCS), sponsored by University of Alabama at Birmingham. Started Aug 2023; status: recruiting.
02
Drugs
cabozantinibdostarlimab
03
Conditions
Gynecologic carcinosarcoma (GCS)
Beyond the preview
Go deeper on NCT05559879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559879.